RenoTact®
Early Detection of Peritonitis
Peritoneal Dialysis (PD) patients are at risk of peritonitis, a severe infection that can lead to treatment failure and increased mortality. Current detection methods rely on measuring a host response and slow culture methods, delaying potentially life-saving interventions.
Results available within
0
Seconds
Chronic Kidney Disease is a worldwide public health problem
Worldwide use of Renal Replacement Therapy (RRT) is projected to more than double to 5.4 million people by 2030.
Current estimates suggest that more than 500,000 patients will receive peritoneal dialysis by 2027, representing approximately 11% of the dialysis population.
With so many people suffering from end-stage renal disease, the demand for diagnostic tools to rapidly identify PD-related infections, is growing fast.
Our Solution
RenoTact®
Peace of Mind with Early Detection
RenoTact® is a rapid, user-friendly test that directly detects causative agents of peritonitis in PD patients. By enabling earlier medical diagnosis and intervention than standard of care methods, RenoTact® provides a tool to support patients to continue peritoneal dialysis (PD) without transitioning to hemodialysis (HD), preserving their quality of life and treatment independence.
How RenoTact® works
Collect
No Sample Prep
Add a small sample of the PD waste fluid to the VIPER® assay tube containing the RenoTact® assay
Read
Reader Agnostic
Place the VIPER® assay tube containing the sample, into the DeNIRO® mini Fluorometer (point-of-care) or plate reader (lab-based testing)
Treat
Actionable Results
RenoTact® provides actionable data within minutes enabling health care professionals to start immediate targeted treatment
Benefits to healthcare providers
Easy to Obtain Sample
Requires only a small volume (100 µL) sample from the peritoneal dialysis waste fluid
Immediate Result
RenoTact® rapidly identifies viable PD-related Peritonitis infections
Improved Quality of Life for Patient
Reduces risk of treatment failure and ensures continuous preferred PD-treatment
Reduces Hospital Admissions
Provides clinicians actionable data to shorten the time to diagnosis and treatment initiation, decreasing emergency interventions
Breakthrough Technology – The VIPER® platform detects active infections with accuracy and speed
RenoTact® is currently for research use only and is not for use in diagnostic procedures; the performance characteristics of this product have yet to be established